What is Remynd?
Remynd is a specialized clinical-stage biotechnology company that emerged as a spin-off from the University of Leuven in 2002. The firm is primarily focused on developing novel therapeutic interventions for diseases characterized by cellular dysfunction, including Alzheimer's, diabetes, and epilepsy. At the core of its operations is a proprietary drug discovery platform that facilitates the identification of novel mechanisms-of-action and targets. Beyond its internal drug development pipeline, which includes the advanced ReS19-T program for Alzheimer's and ReS39 for diabetes, the company operates a dedicated Contract Research Organization (CRO). This division provides specialized services to a global client base, utilizing proprietary animal models to assess the pharmacokinetics and efficacy of experimental treatments for central nervous system disorders.
How much funding has Remynd raised?
Remynd has raised a total of $29.2M across 1 funding round:
Series B
$29.2M
Series B (2021): $29.2M with participation from BNP Paribas Fortis, FPIM, Korys Investments, KU Leuven, and PMV Groupe
Key Investors in Remynd
BNP Paribas Fortis
A prominent Belgian banking institution providing comprehensive financial services and strategic capital support to established and emerging enterprises.
PMV Groupe
An investment firm focused on fostering economic growth in Flanders by providing financing and expertise to innovative companies.
KU Leuven
A world-renowned research university that acts as a foundational partner and incubator for spin-off ventures in the life sciences sector.
What's next for Remynd?
With the successful closure of this major strategic investment, Remynd is well-positioned to transition its lead investigational compounds through more rigorous clinical phases. The strategic roadmap involves scaling the development of its CNS-focused pipeline while simultaneously leveraging its CRO division to generate non-dilutive revenue streams. By maintaining a dual-focus on internal therapeutic innovation and external research services, the company is effectively mitigating the risks typically associated with drug development. Future growth will likely center on expanding its intellectual property portfolio and potentially entering into strategic partnerships with larger pharmaceutical entities to facilitate the commercialization of its most promising candidates. The company remains committed to addressing the root causes of neurodegeneration and metabolic failure, ensuring long-term value creation for stakeholders and patients alike.
See full Remynd company page
